Meetings on Xpert MTB/RIF

May 2012

WHO Expert Group Meeting (WHO-EGM): Policy Guidance on the utility of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary TB in adults and children
Les Pensierès, Veyrier-du-Lac, France
20-21 May 2012

April 2012

4th Annual GLI Meeting/Consultation of the SRL network/Early implementers meeting on Xpert MTB/RIF roll out
Les Pensières, Veyrier-du-Lac, France
17-19 April 2012
Agenda and presentations
List of Participants

May 2011

Consultation: Impact of WHO-endorsed molecular diagnostics on TB and MDR-TB case- and treatment outcome definitions

Agenda
Background Information
List of Participants
Geneva, Thurs + Fri 12-13 May

Presentations:
1.DF_Overview of current MDR-TB case and treatment outcome definitions 12 May 2011
Case and outcome definitions 11May11 Grzemska
Consultation 12-13 May 2011 KWEYER.pptx
Objectives_ExpectedOutcomes Floyd
Objectives_ExpectedOutcomes_20110513
Objectives_ExpectedOutcomes_20110516
revising_casedef_rev_pg
revising_outcomes_defs_pg

April 2011

Implementation and roll-out of the Xpert MTB/RIF system for rapid diagnosis of tuberculosis and multidrug-resistance: Workshop for Early Implementers

Date & time: 7-8 April 2011, 08:00 - 17:00
Venue: Starling Geneva Hotel & Conference Center
34, route François Peyrot, 1218 Le Grand Saconnex, Geneva, Switzerland
Agenda
Background materials

Presentations

Day 1

• Session1a_Timeline of Xpert MTBRIF activities [.pdf]
• Session1b_Workshop scope and objectives [.pdf]
• Session2a_Xpert MTBRIF development, analytical performance and evidence from field evaluation studies [.pdf]
• Session2b_Xpert MTBRIF operational considerations [.pdf]
• Session3a_Risk assessment [.pdf]
• Session3b_Primary considerations_Individuals at risk of MDRTB [.pdf]
• Session3c_Primary considerations_People living with HIV [.pdf]
• Session3d_Secondary considerations [.pdf]
• Session3e_Site selection [.pdf]

Day 2

• Session4a and b_Preferential pricing, installation and startup costs, and post-marketing surveillance [.pdf]
• Session4c_Involvement of the private sector [.pdf]
• Session4d_Uganda experience using Xpert MTBRIF [.pdf]
• Session5a_Interim case definitions MG 8Apr11 [.pdf]
• Session5b_Registration and reporting of TB and MDR-TB [.pdf]
• Session5c_Management of patients with rifampicin resistance [.pdf]
• Session5d_Managing of persons with HIVassociated TB [.pdf]
• Session6a_Plans- CDC_PEPFAR [.pdf]
• Session6a_Plans- FIND EXPAND-TB [.pdf]
• Session6a_Plans- ICAP [.pdf]
• Session6a_Plans- IOM [.pdf]
• Session6a_Plans- KNCV [.pdf]
• Session6a_Plans- Moldova [.pdf]
• Session6a_Plans- MSF [.pdf]
• Session6a_Plans- South Africa NHLS [.pdf]
• Session6a_Plans- USAID [.pdf]
• Session6b_Way forward and next steps [.pdf]
• Session7a_Operational research opportunities and priorities [.pdf]
• Session7b_Operational research and implementation of new TB diagnostics [.pdf]
• Session7b_Xpert operational research mapping tool [.pdf]

February 2011

Update on the implementation and roll out of the Xpert MTB/RIF
Date & time: 21 February 2011, 14:00 - 16:00
Venue: Room 605, Building M, World Health Organization, Geneva

Agenda

Background Materials
Update note on the implementation and roll-out of Xpert MTB/RIF
Roadmap for rolling our Xpert MTB/RIF
Frequently Asked Question on Xpert MTB/RIF
FIND update on operational questions regarding the Xpert MTB/RIF test
Cartridge Video

Presentations
Briefing Xpert MTB-RIF
Implementation of Xpert FM

December 2010

GLOBAL CONSULTATION ON THE IMPLEMENTATION AND SCALE-UP OF THE "GeneXpert MTB/RIF System" FOR RAPID DIAGNOSIS OF TB AND MDR-TB

Date and time: 30 November -02 December 2010, 09:00 - 18:00
Venue: Centre International de Conférences de Genève (CICG)
17, Rue Varembé, Geneva, Switzerland
Agenda

Presentations

Day 1

session 1

• Meeting scope and objectives K Weyer [.pdf]
• New frontiers changing diagnostic paradigms G Roscigno [.pdf]
• Responding to change Rapid policy development by WHO M Raviglione K Weyer [.pdf]

session 2

• Xpert MTB RIF - development and analytical performance M Perkins [.pdf]
• Xpert MTB RIF - evidence and operational considerations C Boehme [.pdf]
• Xpert MTB RIF - update on price negotiations and market dynamics G Roscigno [.pdf]

session 3

• An ethical dillemma - diagnosis without treatment A Reis [.pdf]
• From diagnosis to treatment and care - the missing links P Nunn [.pdf]
• Xpert MTB RIF - opportunity to enhance private sector engagement M Uplekar [.pdf]
• Xpert MTB RIF - scenarios for cost effectiveness A Vassall [.pdf]
• Xpert MTB RIF in the Global plan 2011-2015 - what it will cost K Floyd [.pdf]

session 4

• Civil society perspective F Varaine [.pdf]
• Civil society perspective J Syed [.pdf]
• Pateint Perspectives on GeneXpert L Chesire N Otwoma [.pdf]
• Use of Xpert MTB RIF in the private sector - Pakistan A Khan [.pdf]

session 5

• Global Consultation Algorithm Xpert DOTS Expansion [.pdf]
• Global Consultation Algorithm Xpert TBHIV [.pdf]
• Global Consultation Xpert Algorithm MDR-TB [.pdf]

Day 2

• Discussion on diagnostic algorithm with Xpert DOTS Expansion [.pdf]
• Discussion on diagnostic algorithm with Xpert MDR-TB [.pdf]
• Discussion on diagnostic algorithm with Xpert TB HIV [.pdf]

Day 3

• Country plan for scaling up Xpert MTB-RIF G Coetzee [.pdf]
• Final diagnostic algorithm with Xpert MDR D Falzon [.pdf]
• Final diagnostic algorithm with Xpert DOTS Expansion S Sahu [.pdf]
• Final diagnostic algorithm with XpertTB HIV D Sculier [.pdf]
• Global Roadmap for scaling up Xpert MTB-RIF K Weyer [.pdf]
• Increasing access to vulnerable groups through TB REACH L Ditiu [.pdf]
• Learning by doing through EXPAND-TB E Adam [.pdf]
• Mobilising country capacity through TB CARE A Piatek [.pdf]
• Targeting HIV settings through PEPFAR B Coggin [.pdf]
• Xpert_TBHIV_ambulatory_02 12 10_v1 [.pdf]
• Xpert_TBHIV_seriously ill_02 12 01_v1doc [.pdf]